Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05108623 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
A Phase 1 study of Tumor, Solid, sponsored by MiNK Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 8
- Study locations
NCT05108623: Completed Phase 1 study of Tumor, Solid, sponsored by MiNK Therapeutics.
NCT05108623 is a Phase 1 study of Tumor, Solid that has completed, run by MiNK Therapeutics. The registered enrollment target is 34 participants, below the 240-participant average among 11 other Tumor, Solid trials with a reported enrollment target (86% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05108623, a Phase 1 study of Tumor, Solid, has completed, sponsored by MiNK Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed/refractory (r/r) solid tumors, as well as define the recommended phase II dose in solid tumors. This Phase 1 study will also explore the safety, tolerability, and preliminary clinical activity of agenT-797 in combination with approved immune checkpoint inhibitors (ICIs), including pembrolizumab and nivolumab, in participants with r/r solid tumors.
Primary Outcome
This will be determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0).
Conditions Studied
Interventions
- DRUG agenT-797
- DRUG Approved ICIs
Study Locations (8)
California
- University of Southern California - Los Angeles
Colorado
- University of Colorado - Aurora
Kentucky
- Norton Cancer Health - Louisville
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Ohio
- University of Cincinnati Cancer Center - Cincinnati
Oregon
- Providence Portland Medical Center - Portland
Rhode Island
- LifeSpan - Rhode Island Hospital - Providence
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-01-28 |
| Est. Completion | 2024-01-02 |
| Phase | Phase 1 |
What the finished NCT05108623 record still lists
NCT05108623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 240-participant average among 11 other Tumor, Solid trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Tumor, Solid appearing as the primary indexed condition, and to 2 interventions - of which agenT-797 is the first listed.
NCT05108623 lists 8 locations in 8 states (California, Colorado, Kentucky).
Frequently Asked Questions
What is clinical trial NCT05108623 about?
NCT05108623 is a clinical study titled "A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors". This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed/refractory (r/r) solid tumors, as well as define the recommended phase II dose in solid tumors. This Pha...
What is the current status of trial NCT05108623?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2022-01-28. Estimated completion is 2024-01-02.
What conditions does trial NCT05108623 study?
This clinical trial studies the following conditions: Tumor, Solid.
What interventions are being tested in trial NCT05108623?
The interventions under investigation include: agenT-797 (DRUG), Approved ICIs (DRUG).
Who is sponsoring clinical trial NCT05108623?
This trial is sponsored by MiNK Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05108623 being conducted?
This trial has 8 study locations across California, Colorado, Kentucky, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumor, Solid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05108623's enrollment target sits among peer trials
34 10th of 11 higher than 2 of 11 other Tumor, Solid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumor, Solid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
TumorGlow Intraoperative Molecular Imaging (IMI)
RECRUITING · Phase 1
-
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
RECRUITING · Phase 1
-
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
RECRUITING · Phase 1
-
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI